ARCHIVES

Tafinlar Subgroup Data Shows Median OS of 20 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: New Clinical Oncology RFP Ready Soon; CCIRC, Joftes Agree On Funding Method For Symposia

March 9, 1979

Dendreon’s Provenge Approved For Prostate Cancer Treatment

April 30, 2010

Unclear Whether Insurance Will Cover AACR Losses

April 25, 2003

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

CAB Reluctantly Approves Use Of Contract To Support Cancer Journals

February 15, 1985

Scientific Process

September 25, 1998